KBC Group NV Grows Stock Holdings in Astrana Health, Inc. (NASDAQ:ASTH)

KBC Group NV raised its position in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 108.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,530 shares of the company’s stock after buying an additional 1,316 shares during the quarter. KBC Group NV’s holdings in Astrana Health were worth $80,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Janus Henderson Group PLC purchased a new position in shares of Astrana Health in the 3rd quarter valued at approximately $1,164,000. Royce & Associates LP purchased a new position in shares of Astrana Health in the 3rd quarter valued at approximately $6,661,000. Amalgamated Bank purchased a new position in shares of Astrana Health in the 3rd quarter valued at approximately $713,000. Principal Financial Group Inc. purchased a new position in shares of Astrana Health in the 3rd quarter valued at approximately $13,383,000. Finally, Loomis Sayles & Co. L P purchased a new position in shares of Astrana Health in the 3rd quarter valued at approximately $30,251,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ASTH. Truist Financial decreased their price objective on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, January 13th. Macquarie upgraded shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Robert W. Baird increased their price target on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, TD Cowen started coverage on shares of Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $63.67.

Astrana Health Price Performance

Shares of NASDAQ ASTH opened at $35.78 on Monday. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of 27.52, a PEG ratio of 1.37 and a beta of 1.20. Astrana Health, Inc. has a 12 month low of $29.08 and a 12 month high of $63.20. The firm’s 50 day simple moving average is $35.61 and its 200-day simple moving average is $45.82. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. The business had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same quarter last year, the company earned $0.47 EPS. Analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.